Researchgene therapyophthalmologyocugenclinical trials
Ocugen Completes Enrollment For Phase 3 Trial
6.1
Relevance Score
Ocugen Inc. (NASDAQ: OCGN) announced on March 2 that it completed enrollment of 140 patients in its Phase 3 liMeliGhT trial evaluating OCU400 for retinitis pigmentosa. The randomized 2:1 trial is gene-agnostic, uses a single injection per eye, and targets NR2E3 with a 12-month LDNA primary endpoint; topline data are expected in Q1 2027.
Scoring Rationale
Official Phase 3 enrollment news provides credible, timely update; limited novelty and narrow clinical scope reduce broader impact.
Free Career Roadmaps8 PATHS
Step-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Data Analyst
Explore all career paths $95K
Data Scientist$130K
ML Engineer$155K
AI Engineer$160K
Data Engineer$140K
Analytics Eng.$140K
MLOps Engineer$160K
Quant Analyst$175K
Sources
- Read OriginalOcugen Inc. (OCGN): One of the Popular Penny Stocks on Robinhoodinsidermonkey.com
